|
Lars Fruergaard Jørgensen
Lars Fruergaard Jørgensen (born 29 November 1966) is a Danish businessman and has been the chief executive of Novo Nordisk since January 2017. He is the chairman of the European Federation of Pharmaceutical Industries and Associations. Early life and education Jørgensen was educated at the Cathedral School of Viborg.Hannah Kuchler"FT Person of the Year: Lars Fruergaard Jørgensen of Novo Nordisk" ''Financial Times'', 19 December 2023, accessed 6 January 2024 In 1991 Jørgensen earned an MSc in Finance & Business Administration from Aarhus University. Career In 1991, Jørgensen joined Novo Nordisk as an economist in Health Care, Economy & Planning. He was appointed as vice-president for IT and Corporate Development in 2004. In January 2013, he was appointed as executive vice president and chief information officer. In November 2014 oversaw Corporate People & Organization and Business Assurance. In September 2016, it was announced that Jørgensen would succeed Lars Rebien Sà ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Novo Nordisk
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, with production facilities in nine countries and affiliates or offices in five. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes care medications and devices. Novo Nordisk makes the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy. Novo Nordisk is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza. Novo Nordisk employs more than 48,000 people globally, and markets it ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Ozempic
Semaglutide is an anti-diabetic medication used for the treatment of type2 diabetes and an anti-obesity medication used for long-term weight management. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. It can be administered by subcutaneous injection or taken orally. It is sold by Novo Nordisk under the brand names Ozempic and Rybelsus for diabetes, and under the brand name Wegovy for weight management and weight loss. Semaglutide is a glucagon-like peptide-1 receptor agonist. The most common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation. It was approved for medical use in the US in 2017. In 2022, it was the 48th most commonly prescribed medication in the United States, with more than 13million prescriptions. Medical uses In the US, semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type2 diabetes; and to reduce the risk of major adver ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
